Explore

Trendline Trendline
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches

Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches

Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Trendline Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Trendline Trendline
Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill
Trendline Trendline
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress

EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress

EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
Trendline Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays

Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays

Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays